Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11614276 | 0.98 | CYP2A6 (0.96) | CYP2A6KEAP1AXLEGFRLMNA | |
| SCHEMBL10122036 | 0.84 | CYP2A6 (0.72) | CYP2A6KEAP1AXLEGFRLMNA | |
| SCHEMBL394630 | 0.83 | CYP2A6 (0.70) | CYP2A6KEAP1AXLEGFRLMNA | |
| Ethyl Acetate SCHEMBL27658303 | 0.81 | CYP2A6 (0.66) | CYP2A6KEAP1AXLLMNAMAPT | |
| Iodide SCHEMBL7354290 | 0.81 | CYP2A6 (0.68) | CYP2A6KEAP1AXLEGFRLMNA | |
| SCHEMBL11086335 | 0.79 | CYP2A6 (0.62) | CYP2A6KEAP1AXLEGFRLMNA | |
| SCHEMBL1465847 | 0.78 | CYP2A6 (0.63) | CYP2A6KEAP1AXLEGFRMAPT | |
| SCHEMBL75581 | 0.77 | CYP2A6 (0.63) | CYP2A6KEAP1AXLMAPTKDM4E | |
| SCHEMBL10172983 | 0.77 | CYP2A6 (0.63) | CYP2A6KEAP1LMNAMAPTKDM4E | |
| SCHEMBL6019304 | 0.77 | CYP2A6 (0.63) | CYP2A6KEAP1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878947-A2 | MATURATION OF MAMMALIAN HEPATOCYTES | Takara Bio Europe AB (SE) | 2021-09-15 | — | — | EP | claimed |
| US-20210189332-A1 | MATURATION OF MAMMALIAN HEPATOCYTES | TAKARA BIO EUROPE AB (SE) | 2021-06-24 | — | — | US | claimed |
| US-10913932-B2 | Maturation of mammalian hepatocytes | TAKARA BIO EUROPE AB (SE) | 2021-02-09 | — | — | US | claimed |
| CN-109456216-A | A kind of no catalyst is reacted without aromatic amine under the conditions of promotor with the amine that turns of amide derivatives | 湘潭大学 | 2019-03-12 | — | — | CN | claimed |
| US-20190024044-A1 | MATURATION OF MAMMALIAN HEPATOCYTES | TAKARA BIO EUROPE AB (SE) | 2019-01-24 | — | — | US | claimed |
| EP-3303566-A2 | MATURATION OF MAMMALIAN HEPATOCYTES | Takara Bio Europe AB (SE) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193441-A2 | MATURATION OF MAMMALIAN HEPATOCYTES | TAKARA BIO EUROPE AB (SE) | 2016-12-08 | — | — | WO | claimed |
| US-9486892-B2 | Polishing composition | FUJIMI INCORPORATED (JP) | 2016-11-08 | — | — | US | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2008128750-A2 | PROCESS FOR THE MANUFACTURE FOR NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-10-30 | — | — | WO | claimed |
| EP-1982976-A1 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | Intendis GmbH (DE) | 2008-10-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | claimed |
| CN-101036877-A | Hydrophobic charge chromatogram abduction medium by obtaining protein from fermentation supernatants liquid directly and the preparing method | UNIV TIANJIN (CN) | 2007-09-19 | — | — | CN | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | CYP2A6 1392/4885KEAP1 703/4885AXL 3291/4885 |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | CYP2A6 4192/4885KEAP1 3269/4885AXL 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.